source
- Cullinan-Taiho eye FDA filing for zipalertinib after trial shows strong PFS benefit despite three deathsCullinan Therapeutics and its partner Taiho Oncology said they will seek FDA approval for zipalertinib, an oral therapy for a subset of non‑small cell lung cancer, based on data from a late‑stage s…
- New documents expose flaws in Medicare’s rushed AI prior-authorization pilotNew internal documents have highlighted serious shortcomings in Medicare’s recently launched AI-driven prior‑authorization pilot, which was rolled out faster than anticipated. The pilot, designed…